Picuris Pueblo uses genetic testing and finds ties to Chaco Canyon
'It's what we always talked about, what was passed on through generations – through our fore-fathers and our elders, that we had that connection,' said Picuris Pueblo Governor Wayne Yazza Jr.
Governor Yazza Jr. of the Picuris Pueblo says they always knew they had ties to Chaco Canyon, but didn't have the hard evidence to prove it. When non-Pueblo parties started conversations such as drilling in the area, Picuris leaders say they felt left out.
All Pueblo Council of Governors voice support for legislation to permanently protect Chaco Canyon
'Chaco Canyon was being mined, drilled, being basically in a position where we could lose it,' said Picuris Pueblo Lt. Governor Craig Quanchello.
That's when leaders decided they could use genetic testing to trace their DNA back to the site. Hoping to get a say on the land, they partnered with a scientist in Denmark and a professor at Southern Methodist University.
'There are controversial aspects to this. Not everybody agrees with doing ancient DNA. But Picuris knows its identity, they know they've been there for over 1,100 years. They know they would like to know more,' said Professor Mike Adler, Southern Methodist University.
The Picuris Pueblo has a population of about 300 people. The lieutenant governor says having this genetic data would also open opportunities for them to learn about their medical history and tailor medicine to their genetic makeup.
Governor signs bill protecting students' right to wear Native American regalia
'Looking at the world legally, there's all these disputes, whether it land, sacred sites, monuments, it all ties together at the end of the day. Having this DNA, it's a game-changer. It's a tool that we can use to our advantage,' said Yazza Jr.
Picuris leaders say they hope this will open the door for future productive conversations surrounding Chaco. 'At the end of the day, it's protecting Chaco. That was the big thing of tracing it. Letting them know that that's a sacred place to all tribes,' said Yazza Jr.
The data collected is also completely controlled by the Pueblo. Meaning if any researchers wanted access in the future, they would need to get their permission.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
2 days ago
- Newsweek
Breastfeeding Reduces Risk of Early Puberty
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Kids who are exclusively breast-fed as infants are less likely to experience early puberty. This is the conclusion of South Korean researchers who studied the development and infant diets of more than 300,000 children. The team found that breastfeeding during the first four–six months of life was linked with a lower risk of so-called "central precocious puberty" (CPP) in both boys and girls. This association was partially mediated by differences in body weight throughout childhood, with childhood obesity linked to early pubertal onset. While it can lead to an early growth sport compared to other children, adults who went through early puberty tend to be shorter on average. CPP has also been linked to an increased risk of anxiety, depression and low self-esteem. Early puberty has also been associated with an increased risk of substance abuse, eating disorders and having sex at an early age. In women, early puberty is also known to increase the risk of breast cancer as adults. CPP has been on the rise globally, a trend that doctors Lin Yang and Shengxu Li—who were not involved in the study, but authored an accompanying comment paper—say is "particularly concerning given the growing prevalence of childhood obesity." The findings, the researchers note, add to the growing body of evidence highlighting the critical role of early-life nutrition in long-term health. A woman breastfeeds her newborn baby. A woman breastfeeds her newborn this nationwide, retrospective study, researchers compared the incidence of early puberty among children who were exclusively breastfed, formula-fed or mixed-fed during their first four to six months of life. Compared to exclusively breastfed children, formula-fed children had the greatest risk of CPP in boys and girls, followed by mixed-fed boys and girls. In their commentary paper, Yang and Li noted that the findings "contradict prior claims that breastfeeding is unrelated to the timing of pubertal onset in non-Western settings." They explained that the study's findings "suggest a potential developmental pathway through which infant feeding may influence early weight gain and the subsequent pubertal timing." However, they also acknowledged that the source of these associations remains uncertain, and that it is not yet clear whether excess body fat directly contributes to the activation of the hypothalamic-pituitary-gonadal axis—a hormonal pathway that regulates reproduction and development—or regulates upstream signals like the hypothalamic kisspeptin system, responsible for regulating the onset of puberty. The duo highlighted the study's importance in filling a research gap on puberty timing in boys. They noted: "Boys who were exclusively formula-fed had a 16 percent increased risk of CPP compared with those who were exclusively breastfed, and [excess body fat] mediated this association in a pattern similar to that observed in girls." The experts pointed out that this increase in CPP risk observed in boys contrasts with the 60 percent increase observed in girls—which might help explain the lack of similar reports on puberty timing in boys. Ultimately, the study's findings support the view that breastfeeding during early infancy may help protect against CPP in both sexes. As Yang and Li concluded: "Disease starts early, so should its prevention." Do you have a tip on a health story that Newsweek should be covering? Do you have a question about CPP? Let us know via health@ References Choe, Y., Ryu, S., Choi, J., Na, J. Y., Lee, K. S., Kim, Y. J., & Yang, S. (2025). Breastfeeding, prepubertal adiposity, and development of precocious puberty. JAMA Network Open, 8(8). Yang, L., & Li, S. (2025). Breastfeeding, adiposity, and precocious puberty in boys and girls. JAMA Network Open, 8(8).
Yahoo
2 days ago
- Yahoo
Six year study on Spaceport America's economic impact on New Mexico released
LAS CRUCES, N.M. (KRQE) – A six-year study on Spaceport America's economic impact on New Mexico was released this month and found that the Spaceport showed growth from 2019 to 2024. 'The results are significant, showing that Spaceport America in 2024 supported 313 direct jobs and 790 total jobs in New Mexico, up from 242 direct jobs and 396 total jobs in 2019, while contributing nearly $240 million to economic output, up from $72 million in 2019,' Arrowhead Center program director and co-author of the report Dr. Kramer Winingham stated in a news release. Story continues below News: District Attorney joins City of Albuquerque against lawsuit filed by homeless group Investigation: The Rio Grande Murders: New Mexico's most notorious unsolved crime New Mexico News Insiders: Addressing Education With New Mexico's Lt. Governor Trending: Mother charged after child tests positive for cocaine in Albuquerque The report was published by New Mexico State University (NMSU) Arrowhead Center and the Center for Border Economic Development (C-BED) and covers the spaceport's tenant employment, privately funded construction, out-of-state visitor spending, spaceport revenues, tax revenue impact, and total economic impact. 'Most recently, our estimates indicate Spaceport America has totaled $110.8 million in value-added production and $73.1 million in labor income for our state in 2024,' Winingham added. The study found the spaceport's competitive advantages about restricted airspace access, weather, and elevation draw tenants to New Mexico and can continue to support growth in the future. 'We are excited to see these numbers and the growing contribution the spaceport is making to the region,' Scott McLaughlin, executive director of the NMSA, the state agency that designed, developed, and oversees operations of Spaceport America, stated in the release. 'Besides bringing jobs and new money to New Mexico, Spaceport America is also helping Space Valley to grow and get noticed by the national aerospace community.' Companies in the commercial space industry that are tenants at Spaceport America include Virgin Galactic, HAPSMobile/ AeroVironment, UP Aerospace, Prismatic Ltd., Swift Engineering, Isotropic, ISC/Sirius Technologies, and SpinLaunch. Additional customers Spaceport America partners with include the United States Air Force Thunderbirds, Venus Aerospace, and Precision AI. The report is the second economic impact study released by the New Mexico Spaceport Authority (NMSA) and the Arrowhead Center/C-BED team. Click here to view the full report. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Solve the daily Crossword
Yahoo
11-08-2025
- Yahoo
Boehringer's Hernexeos receives fast-tracked FDA approval
Boehringer Ingelheim has received fast-track approval from the US Food and Drug Administration (FDA) for its targeted therapy, Hernexeos (zongertinib tablets), to treat non-small cell lung cancer (NSCLC). This approval succeeds the positive results of the Phase Ib Beamion-LUNG 1 trial (NCT04886804), with the oral tyrosine kinase inhibitor (TKI) demonstrating an objective response rate (ORR) of 75% in patients with HER2-positive NSCLC who had received prior lines of platinum-based chemotherapy. Its FDA approval makes it the first oral treatment for HER2-positive NSCLC. Hernexeos also triggered a duration of response (DOR) of more than six months in 58% of the 71 patients previously treated with chemotherapy alone, while 27% of the 34 individuals with prior exposure to chemotherapy and a HER2 targeted therapy experienced a DOR of this length. Impacting 2%-4% of patients diagnosed with NSCLC, HER2 mutations are associated with poor prognosis and a higher risk of brain metastasis, while treatment options are highly limited in this population. Due to Hernexeos' potential to fulfil unmet needs in this indication, the FDA granted Boehringer priority review and breakthrough therapy designation last year. The therapy's full approval will likely rely on verification of clinical benefit in a confirmatory trial. Dr John Heymach, co-ordinating investigator on the Beamion-LUNG 1 trial and chair of thoracic/head and neck medical oncology at the MD Anderson Cancer Centre, said: 'The approval of zongertinib offers an effective and targeted treatment option for patients with HER2-mutant NSCLC in the US that not only elicits a durable response, but also has a manageable safety profile. 'In a patient population where there are currently limited treatment options, this approval represents a significant advancement in cancer care.' HER2-targeted therapy race heats up Though the current standard of care (SoC) for patients with HER2-mutated NSCLC still revolves around a platinum-based chemotherapy regimen, physicians are increasingly prescribing targeted therapies to improve outcomes. A notable example of this is AstraZeneca and Daiichi Sankyo's antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan), which became the first HER2-targeting therapy to receive approval for NSCLC in 2022. Following its accelerated FDA approval, the drug has already reached blockbuster status – raking in $4.1bn in 2024 for the company, according to Pharmaceutical Technology's parent company, GlobalData. GlobalData predicts that the drug is on track to pull in $14.6bn by 2031, highlighting the lucrative nature of the targeted oncology market. However, Hernexeos has demonstrated a higher ORR of 75% compared with Enhertu's 56% in the DESTINY-Lung02 trial. The TKI has also proved efficacious in patients who had previously received treatment with an ADC, suggesting that the TKI could absorb some of Enhertu's market share. Looking ahead, the drug may also face competition from other targeted therapies currently in Phase III clinical trials, with GlobalData giving Bayer's TKI sevabertinib a likelihood of approval (LoA) score of 81% in this indication. "Boehringer's Hernexeos receives fast-tracked FDA approval" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
